Compare F5 Inc (FFIV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs Tango Therapeutics Inc. — how do they compare? F5 Inc trades at $460.11 (market cap $26.97B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: F5 Inc is far larger — about 7.2× Tango Therapeutics Inc.'s market cap, and F5 Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold F5 Inc for 38 Days and Tango Therapeutics Inc. for 0 Days on average.
| FFIV | TNGX | |
|---|---|---|
Market Cap | $26.97B | $3.75B |
Volume | 706,169 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $479.83 | $32.90 |
52-Week Low | $223.99 | $7.50 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | $25.61B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $457.26, down 3.43% on the day, amid a bullish technical trend and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $4.73 surpassing the $4.00 expectation. Revenue grew to $3.09 billion in 2025, and net income margin improved to 21.95%. Recent news highlights F5's leadership in WAAP platforms and AI security innovations, reinforcing its competitive edge.
The outlook remains positive given earnings momentum and strategic positioning in application security, though valuation multiples like a P/E of 37.95 suggest premium pricing. Risks include competitive pressures and market volatility. Analyst consensus is mixed with a $416.60 price target below the current price, indicating potential near-term caution despite long-term growth prospects.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
